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Abstract. A silica–protein hybrid material has been prepared by simultaneous 
covalent deposition of apoferritin and lactoferrin on functionalized silica. This 
material exhibits strong antibacterial activity against E. coli due to its high iron-
uptake capacity. 
 
As bacteria are able to infect almost all tissues in the human body, they cause a spectrum 
of illnesses ranging from common skin infections to severe and fatal diseases. Indeed, 
bacterial infection is one of the leading causes of death in the world. Furthermore, 
some bacteria have developed aremarkable ability to resist currently available 
antimicrobials, thus highlighting the need for the development of new antimicrobial 
agents. A promising strategy in this respect involves inhibiting their ability to obtain the 
nutrients required for growth.1 An effective route to combat bacterial infection is to 
create materials that can compete with bacteria for iron, thereby depriving them of 
this metal, which they need to proliferate. However, such a route must be more 
efficient in terms of iron uptake than siderophores, low-molecular-weight iron 
chelators that are produced and exported by bacteria during periods of nutrient 
deprivation.2 A good alternative to the creation of new materials for this purpose is 
to mimic existing and efficient biological systems.  nimals closely regulate iron 
levels3 and sequester this nutrient as a mechanism of preventing bacterial 
proliferation. Two kinds of proteins, namely transferrins (including lactoferrin), 
which are glycoproteins that remove extracellular Fe(III) due to their high Fe(III) 
affinity,4,5 and ferritin, which stores the iron that is not required for immediate 
metabolic purposes, play a crucial role in this mechanism.6,7 
Lactoferrin is considered to be one of the key components of the immune system, 
partly due to its high affinity for Fe(III),8,9 and ferritin consists of a spherical 
protein shell (apoferritin) surrounding an aqueous cavity that incorporates Fe(II), 





therein.6,7 The apoferritin shell is assembled from 24 polypeptide chains of two 
types, namely heavy (H) (21 kDa) and light (L) subunits (19 kDa). It has 
traditionally been thought that H-subunits play a key role in Fe(II) oxidation as 
they contain catalytic ferroxidase centres, whereas L-subunits are associated with 
Fe(III) nucleation.6 However, it is interesting to note that pure L ferritin has not 
been found in iron storage organs. All known ferritins always contain at least a 
small amount of H subunits (10% in the liver, for example). As such, it seems that 
the iron uptake and storage process requires the oxidative activity of at least a 
small number of H subunits. Nevertheless, pure or H-rich ferritin is frequently 
found in humans, especially in breast milk, the heart or serum, probably due to its 
strong ferroxidase activity, which helps to protect against toxic Fe(II).10 
In light of these findings, we considered that H-apoferritin and lactoferrin could be 
an effective combination for iron uptake. Interestingly, breast milk contains both 
lactoferrin and apoferritin, the latter of which is an H-rich or H-pure apoferritin.10 
As a result, we supposed that a material capable of confining both H-apoferritin 
and lactoferrin could constitute an effective system for Fe(II) uptake as Fe(II) 
would be oxidized by apoferritin to Fe(III), some of which would be stored in its 
cavity, with the remainder, and any available Fe(III), being captured by lactoferrin. 
In this sense, it is interesting to note that most previous iron uptake strategies 
based on molecular recognition technologies11 involve solids containing 
immobilized molecules with a well-known affinity for  e(III), such as 
desferrioxamine,12 3-hydro-xypyridin-4-ones,13 or EDTA derivatives.14 Despite the 
fact that free Fe(II) is markedly more dangerous than Fe(III) as it catalyses the 
production of reactive oxygen species, which are extremely powerful oxidizing 
agents that are capable of causing extensive cell damage, no hybrid solids with 
iron(II) molecules have been reported. 
The aim of this work was therefore to create new materials containing both 
apoferritin (especially H pure) and lactoferrin to remove iron from the media, thus 
depriving pathological microorganisms of this metal. To achieve this goal, we 
decided to use a vinyl sulfone silica functionalized with both proteins in a step-by-
step manner. The resulting hybrid silica–protein material spatially confines both 
proteins and mimics breast milk to some extent, thus making it potentially useful 





lactoferrin combination for iron uptake.  
The functionalization of silica with vinyl sulfone commences with the silanization 
of commercial silica followed by the Michael-type addition of a bis-vinyl sulfone. 
This process gives rise to a functionalized silica containing available vinyl sulfone 
groups to which different biomolecules can be covalently attached (ESI 1).15 
We initially analysed the reactivity of each protein with the vinyl sulfone silica. 
Under similar conditions, the two apoferritins studied [horse spleen (HSFt) and H-
recombinant (HFt)] showed a higher reactivity than lactoferrin, therefore we first 
carried out the immobilization of a default apoferritin followed, in a second step, 
by an excess of lactoferrin (Scheme 1). Both protein immobilizations were 
performed by incubating the aforementioned proteins with the vinyl sulfone silica 
in phosphate buffer at pH 7.5.‡ After 24 h of incubation with apoferritin, the 
resulting solid was exhaustively washed with buffer (1 M NaCl) to remove the non-
covalently immobilized apoferritin. UV-visible spectroscopic analysis of the wash 
solution showed practically no signal for both HSFt and HFt, thus confirming that 
almost all the apoferritin had bound covalently to the vinyl sulfone and that 
negligible amounts of protein were retained by non-covalent interactions (Fig. 1). 
Once the silica–apoferritin material had been isolated, it was incubated with an 
excess of lactoferrin and, after 24 h, the solid containing both proteins (silica–Ft + 
Lf hereafter) was rinsed and dried at room temperature. 
 
 









Fig 1. UV-visible spectra of proteins (H-apoferritin and lactoferrin) before and after 
incubation with silica (left) and silica–apoferritin (right). Dashed lines correspond to 
the spectra of the wash solution (non-covalent bound protein).  
 
From the difference in the absorbance values of both protein solutions at 280 nm 
before and after incubation with vinyl sulfone silica, and after subtracting the small 
amount of protein removed upon washing the solid (Fig. 1), values of 33.0 mg (for 
apoferritin) and 4.6 mg per gram of vinyl sulfone silica (for lactoferrin) were 
obtained. Note that the absorbance at 280 nm for the solution obtained after 
washing the silica–HFt + Lf material is minimal. Furthermore, if this solution is 
mixed with the supernatant solution and dialyzed using a molecular weight cut-off 
of 100 kDa (larger than the molecular weight of lactoferrin), no absorbance at 280 
nm is observed at all, thus confirming that apoferritin is not displaced by the 
covalent attachment of lactoferrin and that both proteins are definitely fixed to the 
silica. 
Once isolated, the hybrid silica–Ft + Lf materials were incubated with an Fe(II) 
solution (5 mL, 10 mM) and, after 6 h, the resulting solids centrifuged and washed 
twice with buffer and 1 M NaCl. The supernatant and wash solutions were mixed 
and the iron concentration measured by ICP to quantify the iron removal efficacy 
of the silica–Ft + Lf (silica–HSFt + Lf and silica–Ft + Lf). The results are shown in 
Table 1 along with values for control samples, functionalized vinyl sulfone silica 






The best values were obtained with recombinant H-apoferritin and lactoferrin 
supported on the functionalized silica, which agrees with the expected existence of 
a cooperative effect of both proteins that leads to a very efficient iron uptake. This 
effect is lower in the silica–HSFt + Lf material as a result of the lower ferroxidase 
activity of horse spleen apoferritin with respect to H-pure apoferritin (silica–HFt + 
Lf). Likewise, it is interesting to highlight the low iron removal efficiency of the 
silica containing only lactoferrin (silica–Lf), which exhibits a similar yield to the 
silica containing no protein (silica). This is probably due to the high affinity of 
lactoferrin for Fe(III) but not for Fe(II). However, in the presence of a protein with 
ferroxidase activity, such as apoferritin, which oxidizes Fe(II) to Fe(III), lactoferrin 
multiplies its effectiveness and ultimately makes the apoferritin–lactoferrin 
combination the best option for iron uptake, especially if the apoferritin exhibits a 
high ferroxidase activity, as is the case for H-recombinant apoferritin. 
In light of these promising results, we decided to check the antimicrobial activity of 
the silica–HFt + Lf material against E. coli. The antimicrobial activity of lactoferrin 
against E. coli has been reported both in solution16 or immobilized on the surface 
of a copolymer.17 However, the antimicrobial activity of our hybrid materials is 
based on the cooperative effect of two proteins: first by uptake and oxidation of 
Fe(II) (apoferritin) and ultimately the uptake of Fe(III) (apoferritin + lactoferrin). 
Our hybrid materials are therefore designed to act as antibacterial agents due to 
their ability to sequester Fe(II), the most toxic form of iron. 
 





                
  
Fig 2. Fluorescence microscopy images of E. coli proliferation obtained using a 
Live/Dead Bacterial Viability Kit, where live and dead bacteria exhibit green and red 
emissions, respectively. Silica–HFt + Lf dramatically inhibits bacterial viability.  
 
Bacterial inhibition by silica–HFt + Lf was quantified using the Live/Dead Bacterial 
Viability Kit, counting the number of live (green) and dead (red) bacteria by 
fluorescence microscopy.‡ The average live/dead ratio (viability v) was used to 
quantify the bacterial inhibition effect of the hybrid silica–protein material in 
comparison with control experiments. As can be seen from Fig. 2, the silica–HFt + 
Lf material dramatically decreases the bacterial viability in MRS + cys (viability v = 
0.9), a medium where these bacteria proliferate adequately (viability control v = 
60.5). 
Interestingly, the silica–Lf material, which only contains lactoferrin and removes 
small amounts of iron (Table 1), did not significantly inhibit bacterial viability (v = 
54.5). Likewise, in agreement with its higher iron uptake ability (Table 1), silica–
HSFt inhibits more strongly than silica–Lf (v = 24.1) but is markedly less effective 
as an antibacterial agent than the silica material containing both proteins (silica–





These results demonstrate the antibacterial activity of this novel hybrid silica–HFt 
+ Lf material and confirm that the mechanism of antibacterial activity of this 




The results of this study confirm our initial bio-inspired hypothesis that the 
confinement of apoferritin and lactoferrin supported on a material such as silica is 
a useful route for iron(II) uptake and therefore for use as an antimicrobial agent. A 
high antibacterial activity has been demonstrated against E. coli K-12, especially 
when using the silica containing both H-recombinant apoferritin and lactoferrin. 
Likewise, the correlation between bacterial inhibition and iron uptake confirms 
that the antimicrobial activity of these materials resides in their iron uptake 
capacity. Finally, we are convinced that this kind of material may find use as the 
active ingredient in creams or topical drugs for the treatment of microbial 
infections in cosmetics and personal hygiene. 
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Materials and methods 
‡ The vinyl sulfone silica15 (ESI) (100 mg) was incubated with stirring with the 
protein (2.5 mL, 0.01875 mM) in phosphate buffer at pH 7.5 at 4 ºC. After 24 h, the 
mixture was centrifuged at 10000 rpm for 10 min at 20 ºC. The solid was washed 
with buffer containing 1 M NaCl. Both supernatant solutions, from the first 
centrifugation and washed solid, were mixed and the protein concentration 
measured by the absorbance at 280 nm (ε280HS = 33 900 and ε280HFt = 27 900 M-1cm-1) 
in the UV-visible spectrum. From the difference in the absorbance values at 280 nm in 
the initial protein solution and the mixture of supernatant solutions (after 
centrifugation and after washing), values of 33.0 mg for apoferritin, and 4.6 mg for 





Preparation of vinyl sulfone functionalized silica–lactoferrin + apoferritin (silica–HFt 
+ Lf and silica–HSFt + Lf): the vinyl sulfone silica (100 mg) was incubated with 
stirring with apoferritin (HSFt or HFt) (2.5 mL, 0.01 mM) in phosphate buffer at pH 
7.5 at 4 ºC. After 24 h, the mixture was centrifuged at 10000 rpm for 10 min at 20 ºC. 
The solid was washed with buffer containing 1 M NaCl. The resulting solid (silica–Ft 
or silica–HFt) was incubated with stirring with apolactoferrin (2.5 mL, 0.05 mM) in 
phosphate buffer at pH 7.5 at 4 ºC. After 24 h, the mixture was centrifuged at 10000 
rpm for 10 min at 20 ºC. The solid was washed with buffer containing 1 M NaCl and 
dried at room temperature. Iron uptake by the hybrid silica–protein materials: the 
silica–protein (500 mg) was incubated with a solution of Fe(NH4)2(SO4)26H2O (5 mL, 
10 mM) for 6 h without stirring and then centrifuged at 10000 rpm for 10 min at 20 
ºC. The solid was washed with a 1 M NaCl solution. The supernatant solution from the 
centrifugation and the washed solution were mixed and the iron concentration 
measured by Inductive Coupled Plasma. From the ratio between final and initial iron 
concentration, the yield of iron removal was obtained for each sample (Table 1).  
Inhibition of E. coli K-12: a bacteria culture (400 mL of 1·107 CFU) in MRS + cys was 
subjected to the hybrid material (100 mg) for 16 h. Quantification of bacterial 
proliferation was performed by using the Live/Dead Bacterial Viability Kits SYTO9 
(green) and propidium iodide (red) (Invitrogen), counting the number of live (green) 
and dead (red) bacteria in a batch of three experiments using the Image-Pro Plus 6.0 
software. The average live/dead ratio (viability v) was used to quantify the effect of 
the hybrid material on bacterial inhibition by comparing with control experiments 
where no silica–protein material was present. The presence of silica–HFt + Lf resulted 
in a decrease in viability to 0.9 with respect to control experiments where the 











Electronic Supplementary Information (ESI) 
 
 
Scheme SI1. Synthetic route for the preparation of the vinyl sulfone silica. 
 
Preparation of mercaptoethanol functionalized silica 2 (Scheme 1). Chloro 
functionalized silica 1 (5.0 g) was suspended in acetonitrile (40 mL) and then 2-
mercaptoethanol (3.5 mL) and potassium carbonate (6.9 g) were added. The 
magnetically stirred suspension was heated at 50 ºC under an Ar atmosphere for 8 h. 
The reaction mixture was filtered and the white powder washed with hot water (2 x 
20 mL) and finally with acetone (2 x 20 mL) and dried under vacuum (1mmHg) at 50 
ºC for 16 h giving the mercaptoethanol functionalized silica 2 (4.2 g). 
Preparation of ethanol sulfone functionalized silica 3 (Scheme 1). Mercaptoethanol 
functionalized silica 2 (3.0 g) was suspended in acetic acid (6.0 mL) and then 
hydrogen peroxide 33% (15.0 mL) was added. The magnetically stirred reaction 
mixture was kept at room temperature for 24 h in the absence of light. After 
filtration, the white powder was washed with water (2 x 20 mL), methanol (2 x 20 
mL) and finally acetone (2 x 20 mL), and dried under vacuum (1 mmHg) at 50 ºC for 
16 h giving the ethanol sulfone functionalized silica 3 (2.9 g) 
Preparation of vinyl sulfone functionalized silica 4 (Scheme 1). Ethanol sulfone 
functionalized silica 3 (2.5 g) was suspended in anhydrous dichloromethane (40 mL). 
The magnetically stirred suspension was cooled at 0 ºC by means of an ice bath. 
Methanesulfonyl chloride (0.9 mL) and triethylamine (3.5 ml) were then added. After 
the addition of the reagents, the reaction mixture was kept at room temperature for 
7 h and then filtered. The white powder was washed with methanol (2 x 20 mL) and 
acetone (2 x 20 mL), and dried under vacuum (1mm Hg) at 50 ºC for 16 h giving the 





Proteins. Recombinant H apoferritins were obtained from Molirom and was 
exhaustively dialyzed against milli-Q water using a Spectra/Por Float-A-Lyzer with a 
molecular weight cut-off (MWCO) of 300.000 Da. Horse spleen apoferritin and human 
apolactoferrin were purchased from Sigma and used as received. 
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